2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 374

The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Abstract Number: 375

Experience with Biologic Agents for the Treatment of Cardiac Sarcoidosis in a U.S. Academic Medical Center
Abstract Number: 376

Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study
Abstract Number: 377

Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Abstract Number: 378

Systemic and Ocular Sarcoidosis Study of 381 Patients from a Single Universitary Centre in the Last 20 Years
Abstract Number: 379

Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group
Abstract Number: 380

Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution
Abstract Number: 381

Effect of Vitamin D Supplementation on Calcium Levels in Patients with Sarcoidosis: A Retrospective Analysis
Abstract Number: 382

Neurofilament Light Chain Levels in Cerebrospinal Fluid and Plasma in Neurosarcoidosis
Abstract Number: 383

Retroperitoneal Fibrosis- a Single Center Experience
Abstract Number: 384

Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease
Abstract Number: 385

Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease
Abstract Number: 386

Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain
Abstract Number: 387

Early Mortality in IgG4-Related Disease
Abstract Number: 388

Treating Statin-induced Anti-HMGCR Myopathy with Normal Muscle Strength: A New Window of Opportunity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.